




RealRate

PHARMACEUTICAL 2022

International Stem Cell CORP
Rank 215 of 475



RealRate

• Financial Strength Rankings using Artificial Intelligence • www.realrate.ai



RealRate

PHARMACEUTICAL 2022

International Stem Cell CORP Rank 215 of 475



The relative strengths and weaknesses of International Stem Cell CORP are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of International Stem Cell CORP compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 551% points. The greatest weakness of International Stem Cell CORP is the variable Cost of Goods Sold, reducing the Economic Capital Ratio by 197% points.

The company's Economic Capital Ratio, given in the ranking table, is -78%, being 199% points above the market average of -276%.

Input Variable	Value in 1000 USD
Assets, Current	2,334
Cost of Goods Sold	2,935
Intangible Assets	949
Liabilities, Current	4,284
Liabilities, Non-Current	950
Other Assets	1,279
Other Compr. Net Income	0
Other Expenses	1,383
Other Liabilities	0
Other Net Income	1,022
Property and Equipment	384
Research and Development	695
Revenues	7,176
Selling, General and Administrative Expense	4,084

Output Variable	Value in 1000 USD
Assets	4,946
Liabilities	5,234
Expenses	9,097
Stockholders Equity	-288
Net Income	-899
Comprehensive Net Income	-899
Economic Capital Ratio	-78%



RealRate

• Financial Strength Rankings using Artificial Intelligence • www.realrate.ai